CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Viridian Therapeutics, Inc. - VRDN CFD

    15.72
    0.76%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.14
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Viridian Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 15.89
    Open* 15.85
    1-Year Change* -29.77%
    Day's Range* 15.58 - 16.09
    52 wk Range 10.93-39.00
    Average Volume (10 days) 769.70K
    Average Volume (3 months) 15.92M
    Market Cap 825.60M
    P/E Ratio -100.00K
    Shares Outstanding 52.59M
    Revenue 347.00K
    EPS -5.10
    Dividend (Yield %) N/A
    Beta 1.01
    Next Earnings Date Mar 6, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 27, 2023 15.89 0.28 1.79% 15.61 15.97 14.97
    Nov 24, 2023 16.20 0.55 3.51% 15.65 16.25 15.53
    Nov 22, 2023 15.63 -0.07 -0.45% 15.70 16.02 15.52
    Nov 21, 2023 15.68 -0.10 -0.63% 15.78 16.56 15.62
    Nov 20, 2023 16.16 0.47 3.00% 15.69 16.55 15.47
    Nov 17, 2023 15.84 0.82 5.46% 15.02 15.96 14.66
    Nov 16, 2023 15.16 -0.36 -2.32% 15.52 15.59 14.80
    Nov 15, 2023 15.95 1.34 9.17% 14.61 16.82 14.61
    Nov 14, 2023 15.18 0.67 4.62% 14.51 15.39 14.42
    Nov 13, 2023 13.94 0.33 2.42% 13.61 13.96 13.28
    Nov 10, 2023 13.71 0.53 4.02% 13.18 13.82 12.98
    Nov 9, 2023 13.54 -0.19 -1.38% 13.73 14.11 13.21
    Nov 8, 2023 14.05 -0.27 -1.89% 14.32 14.83 13.87
    Nov 7, 2023 14.71 0.13 0.89% 14.58 15.00 14.55
    Nov 6, 2023 14.87 -0.26 -1.72% 15.13 15.55 14.54
    Nov 3, 2023 15.14 1.09 7.76% 14.05 15.75 14.05
    Nov 2, 2023 14.02 1.44 11.45% 12.58 14.25 12.58
    Nov 1, 2023 12.57 0.09 0.72% 12.48 12.58 11.75
    Oct 31, 2023 12.48 0.01 0.08% 12.47 12.96 12.06
    Oct 30, 2023 12.98 0.46 3.67% 12.52 13.81 12.52

    Viridian Therapeutics, Inc. Events

    Time (UTC) Country Event
    Thursday, November 30, 2023

    Time (UTC)

    16:15

    Country

    US

    Event

    Viridian Therapeutics Inc at Evercore ISI HealthCONx Conference
    Viridian Therapeutics Inc at Evercore ISI HealthCONx Conference

    Forecast

    -

    Previous

    -
    Wednesday, March 6, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Viridian Therapeutics Inc Earnings Release
    Q4 2023 Viridian Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 1.772 2.963 1.05 4.461 8.386
    Revenue 1.772 2.963 1.05 4.461 8.386
    Total Operating Expense 136.076 82.691 111.43 46.44 41.47
    Selling/General/Admin. Expenses, Total 35.182 25.805 13.265 11.346 11.049
    Research & Development 100.594 56.786 27.804 32.806 30.421
    Operating Income -134.304 -79.728 -110.38 -41.979 -33.084
    Interest Income (Expense), Net Non-Operating 4.43 0.315 -0.335 0.106 0.381
    Net Income Before Taxes -129.874 -79.413 -110.715 -41.873 -32.703
    Net Income After Taxes -129.874 -79.413 -110.715 -41.873 -32.703
    Net Income Before Extra. Items -129.874 -79.413 -110.715 -41.873 -32.703
    Net Income -129.874 -79.413 -110.715 -41.873 -32.703
    Total Adjustments to Net Income 0
    Income Available to Common Excl. Extra. Items -129.874 -79.413 -110.715 -41.873 -32.703
    Income Available to Common Incl. Extra. Items -129.874 -79.413 -110.715 -41.873 -32.703
    Diluted Net Income -129.874 -79.413 -110.715 -41.873 -32.703
    Diluted Weighted Average Shares 32.0873 11.9187 3.55707 2.0892 1.97345
    Diluted EPS Excluding Extraordinary Items -4.04752 -6.66288 -31.1254 -20.0426 -16.5714
    Diluted Normalized EPS -4.04752 -6.66288 -11.401 -19.0853 -16.5714
    Depreciation / Amortization 0.3 0.1 0.2 0.288
    Unusual Expense (Income) 0 70.161 2
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0.072 0.098 0.105 1.195 0.256
    Revenue 0.072 0.098 0.105 1.195 0.256
    Total Operating Expense 59.347 72.571 49.171 30.98 29.82
    Selling/General/Admin. Expenses, Total 19.264 21.831 9.854 8.861 8.108
    Research & Development 40.083 50.74 39.317 22.119 21.712
    Depreciation / Amortization
    Operating Income -59.275 -72.473 -49.066 -29.785 -29.564
    Interest Income (Expense), Net Non-Operating 4.212 4.322 3.281 0.88 0.073
    Net Income Before Taxes -55.063 -68.151 -45.785 -28.905 -29.491
    Net Income After Taxes -55.063 -68.151 -45.785 -28.905 -29.491
    Net Income Before Extra. Items -55.063 -68.151 -45.785 -28.905 -29.491
    Net Income -55.063 -68.151 -45.785 -28.905 -29.491
    Income Available to Common Excl. Extra. Items -55.063 -68.151 -45.785 -28.905 -29.491
    Income Available to Common Incl. Extra. Items -55.063 -68.151 -45.785 -28.905 -29.491
    Diluted Net Income -55.063 -68.151 -45.785 -28.905 -29.491
    Diluted Weighted Average Shares 43.2535 42.2423 40.6344 33.7421 27.7623
    Diluted EPS Excluding Extraordinary Items -1.27303 -1.61334 -1.12675 -0.85665 -1.06227
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -1.27303 -1.61334 -1.12675 -0.85665 -1.06227
    Unusual Expense (Income)
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 431.173 200.163 129.611 29.739 65.37
    Cash and Short Term Investments 424.55 196.965 127.639 26.845 62.481
    Cash & Equivalents 155.579 42.299 45.897 24.846 32.606
    Total Receivables, Net 0.102 0.451 0.108 0.024
    Accounts Receivable - Trade, Net 0.102 0.451 0.108 0.024
    Prepaid Expenses 6.521 2.747 1.972 2.786 2.865
    Total Assets 435.091 203.709 131.255 30.262 66.147
    Property/Plant/Equipment, Total - Net 2.936 2.055 0.787 0.523 0.727
    Property/Plant/Equipment, Total - Gross 4.94 3.831 4.23 3.871 3.817
    Accumulated Depreciation, Total -2.004 -1.776 -3.443 -3.348 -3.09
    Other Long Term Assets, Total 0.982 1.491 0.857 0 0.05
    Total Current Liabilities 33.349 13.636 10.674 10.18 6.733
    Accounts Payable 14.234 2.329 0.67 1.096 0.571
    Accrued Expenses 18.827 11.018 9.703 5.108 3.868
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 3.976 2.294
    Total Liabilities 40.027 15.993 11.218 14.508 14.803
    Total Long Term Debt 4.645 0 0 4.328 8.004
    Long Term Debt 4.645 0 4.328 8.004
    Other Liabilities, Total 2.033 2.357 0.544 0 0.066
    Total Equity 395.064 187.716 120.037 15.754 51.344
    Redeemable Preferred Stock 56.677 15.669
    Common Stock 0.414 0.239 0.042 0.349 0.308
    Additional Paid-In Capital 741.067 412.101 218.089 183.574 177.335
    Retained Earnings (Accumulated Deficit) -488.174 -358.3 -278.887 -168.169 -126.296
    Total Liabilities & Shareholders’ Equity 435.091 203.709 131.255 30.262 66.147
    Total Common Shares Outstanding 41.306 23.924 4.23114 2.32424 2.05607
    Short Term Investments 268.971 154.666 81.742 1.999 29.875
    Other Equity, Total -0.39 -0.157 -0.008 0 -0.003
    Other Current Liabilities, Total 0.288 0.289 0.301
    Preferred Stock - Non Redeemable, Net 85.47 118.164 180.801
    Total Preferred Shares Outstanding 0.23959 0.45813 0.39849
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 323.839 346.331 382.602 431.173 437.355
    Cash and Short Term Investments 313.007 334.291 373.858 424.55 431.322
    Cash & Equivalents 111.597 87.082 88.515 155.579 344.21
    Short Term Investments 201.41 247.209 285.343 268.971 87.112
    Total Receivables, Net 0.102 0.102 0.128 0.102 0.398
    Accounts Receivable - Trade, Net 0.102 0.102 0.128 0.102 0.398
    Prepaid Expenses 10.73 11.938 8.616 6.521 5.635
    Total Assets 328.757 351.467 386.642 435.091 440.58
    Property/Plant/Equipment, Total - Net 3.655 3.952 3.058 2.936 2.072
    Property/Plant/Equipment, Total - Gross 4.94
    Accumulated Depreciation, Total -2.004
    Other Long Term Assets, Total 1.263 1.184 0.982 0.982 1.153
    Total Current Liabilities 23.247 28.657 29.588 33.349 25.214
    Accounts Payable 3.735 4.133 7.872 14.234 12.152
    Accrued Expenses 19.224 24.236 21.428 18.827 12.774
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.288 0.288 0.288 0.288 0.288
    Total Liabilities 45.181 35.61 36.093 40.027 31.573
    Total Long Term Debt 20 4.709 4.677 4.645 4.613
    Other Liabilities, Total 1.934 2.244 1.828 2.033 1.746
    Total Equity 283.576 315.857 350.549 395.064 409.007
    Preferred Stock - Non Redeemable, Net 78.235 78.235 78.235 85.47 85.47
    Common Stock 0.437 0.436 0.431 0.414 0.402
    Additional Paid-In Capital 807.339 792.07 771.705 741.067 709.787
    Retained Earnings (Accumulated Deficit) -659.048 -611.388 -556.325 -488.174 -442.389
    Other Equity, Total -0.064 -0.173 -0.174 -0.39 -0.94
    Total Liabilities & Shareholders’ Equity 328.757 351.467 386.642 435.091 440.58
    Total Common Shares Outstanding 43.701 43.5622 43.0553 41.306 40.2444
    Total Preferred Shares Outstanding 0.22365 0.22365 0.22365 0.23959 0.23959
    Redeemable Preferred Stock 56.677 56.677 56.677 56.677 56.677
    Long Term Debt 20 4.709 4.677 4.645 4.613
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -129.874 -79.413 -110.715 -41.873 -32.703
    Cash From Operating Activities -93.838 -54.581 -29.779 -36.056 -26.844
    Cash From Operating Activities 0.255 0.12 0.239 0.288 0.281
    Non-Cash Items 19.819 22.988 76.27 3.878 3.639
    Cash Interest Paid 0.293 0 0.267 0.511 0.489
    Changes in Working Capital 15.962 1.724 4.427 1.651 1.939
    Cash From Investing Activities -115.126 -74.292 -50.481 28.226 -29.907
    Capital Expenditures -0.797 -0.338 -0.042 -0.084 -0.445
    Other Investing Cash Flow Items, Total -114.329 -73.954 -50.439 28.31 -29.462
    Cash From Financing Activities 322.244 125.275 101.311 0.07 41.916
    Financing Cash Flow Items -18.889 -6.948 -1.348 0.033 -2.795
    Issuance (Retirement) of Stock, Net 336.579 132.223 111.226 2.37 44.711
    Issuance (Retirement) of Debt, Net 4.554 0 -8.567 -2.333 0
    Net Change in Cash 113.28 -3.598 21.051 -7.76 -14.835
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -68.151 -129.874 -84.089 -55.184 -25.693
    Cash From Operating Activities -61.973 -93.838 -59.796 -39.128 -21.042
    Cash From Operating Activities 0.105 0.255 0.159 0.097 0.04
    Non-Cash Items 12.336 19.819 15.429 10.173 4.98
    Cash Interest Paid 0.293 0.144 0.067
    Changes in Working Capital -6.263 15.962 8.705 5.786 -0.369
    Cash From Investing Activities -13.295 -115.126 65.477 22.826 8.863
    Capital Expenditures -0.115 -0.797 -0.566 -0.471 -0.179
    Other Investing Cash Flow Items, Total -13.18 -114.329 66.043 23.297 9.042
    Cash From Financing Activities 8.204 322.244 296.23 5.296 0.738
    Financing Cash Flow Items -18.889 -17.963 0
    Issuance (Retirement) of Stock, Net 8.204 336.579 309.639 0.742 0.738
    Issuance (Retirement) of Debt, Net 4.554 4.554 4.554
    Net Change in Cash -67.064 113.28 301.911 -11.006 -11.441
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    VR Adviser, LLC Venture Capital 7.0589 3082622 382757 2023-06-30 MED
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 6.6828 2918369 516557 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 6.2582 2732979 335309 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.9283 2588882 466411 2023-06-30 LOW
    Paradigm BioCapital Advisors LP Investment Advisor 5.5307 2415256 129558 2023-06-30 MED
    Commodore Capital LP Hedge Fund 5.0378 2200000 10341 2023-06-30 MED
    RA Capital Management, LP Hedge Fund 4.598 2007946 0 2023-06-30 LOW
    Perceptive Advisors LLC Private Equity 4.0677 1776386 40000 2023-06-30 MED
    Vivo Capital, LLC Venture Capital 3.8429 1678207 0 2023-06-30 LOW
    Polar Capital LLP Investment Advisor/Hedge Fund 3.6638 1600000 1050000 2023-06-30 LOW
    AllianceBernstein L.P. Investment Advisor/Hedge Fund 3.605 1574302 330152 2023-06-30 LOW
    Fairmount Funds Management LLC Hedge Fund 3.1363 1369623 0 2023-06-30 MED
    Millennium Management LLC Hedge Fund 3.0634 1337788 723699 2023-06-30 HIGH
    Deep Track Capital LP Hedge Fund 2.9299 1279502 49243 2023-06-30 MED
    Yiheng Capital Management, L.P. Investment Advisor 2.8132 1228534 0 2023-06-30 LOW
    Braidwell LP Hedge Fund 2.7623 1206300 1206300 2023-06-30 HIGH
    Logos Global Management LLC Investment Advisor 2.5761 1125000 175000 2023-06-30 HIGH
    Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 2.4308 1061517 18552 2023-06-30 LOW
    Octagon Capital Advisors LP Hedge Fund 2.1136 923000 -262000 2023-06-30 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9713 860857 84745 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Viridian Therapeutics, Inc. Company profile

    About Viridian Therapeutics Inc

    Viridian Therapeutics, Inc. (Viridian) is a biotechnology company that is focused on advancing treatments for patients suffering from serious diseases. The Company’s products include VRDN-001 and VRDN-002. The Company’s advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R). The IGF-1R is a clinically and commercially validated target for the treatment of thyroid eye disease (TED). TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. The Company’s product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology. The VRDN-002 is designed to support the administration as a convenient, low-volume, subcutaneous injection.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Viridian Therapeutics Inc revenues increased from $1.1M to $3M. Net loss decreased 28% to $79.4M. Revenues reflect Collaboration revenue increase from $735K to $3M. Lower net loss reflects Acquired in-process research and develop decrease from $69.9M (expense) to $0K, Interest and other expense decrease of 99% to $3K (expense), Interest and other income increase of 84% to $318K (income).

    Industry: Biotechnology & Medical Research (NEC)

    221 Crescent Street
    Bldg. 17, Suite 401
    WALTHAM
    MASSACHUSETTS 02453
    US

    Income Statement

    • Annual
    • Quarterly

    News

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023
    Gold bars

    XAU/USD Latest: Gold advances as weaker data weighs on US yields

    Gold moves higher as softer economic data weighs on US yields and the dollar

    13:43, 17 November 2023

    People also watch

    XRP/USD

    0.61 Price
    +1.250% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Gold

    2,036.13 Price
    +1.140% 1D Chg, %
    Long position overnight fee -0.0192%
    Short position overnight fee 0.0110%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    Oil - Crude

    76.92 Price
    +2.310% 1D Chg, %
    Long position overnight fee -0.0187%
    Short position overnight fee -0.0032%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    BTC/USD

    37,776.70 Price
    +1.520% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading